Last reviewed · How we verify
Celecoxi + Acetaminophen
Celecoxib selectively inhibits COX-2 to reduce inflammation and pain, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects.
Celecoxib selectively inhibits COX-2 to reduce inflammation and pain, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects. Used for Moderate to severe acute pain, Postoperative pain, Musculoskeletal pain conditions.
At a glance
| Generic name | Celecoxi + Acetaminophen |
|---|---|
| Also known as | Cele + Ace |
| Sponsor | Laboratorios Silanes S.A. de C.V. |
| Drug class | NSAID + Analgesic combination (COX-2 selective inhibitor + acetaminophen) |
| Target | COX-2 enzyme; prostaglandin synthesis pathway |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
This is a fixed-dose combination where celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduces inflammatory mediators with potentially lower gastrointestinal toxicity compared to non-selective NSAIDs. Acetaminophen works through a different mechanism—inhibiting prostaglandin synthesis centrally and peripherally—to provide complementary pain relief and fever reduction. The combination aims to provide enhanced analgesia for moderate to severe pain conditions.
Approved indications
- Moderate to severe acute pain
- Postoperative pain
- Musculoskeletal pain conditions
Common side effects
- Gastrointestinal upset
- Headache
- Dizziness
- Dyspepsia
- Hepatotoxicity (acetaminophen component)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Celecoxi + Acetaminophen CI brief — competitive landscape report
- Celecoxi + Acetaminophen updates RSS · CI watch RSS
- Laboratorios Silanes S.A. de C.V. portfolio CI